INTRODUCTION
Extrahepatic portal hypertension (EHPH) is responsible for up to 2/3 of all the cases of paediatric portal hypertension. This is in contrast to the adults where cirrhosis is the most common underlying cause for portal hypertension. [1, 2] Nonetheless, these children present with similar catastrophic upper gastrointestinal bleed from oesophageal varices. These patients are young, have a preserved liver function, do not have any associated cardiac or renal problems; they tolerate the bleeding episodes well without developing decompensation, coagulopathy or encephalopathy. The natural history of untreated paediatric EHPH has not been well documented.
The management of these patients has turned a full circle in the last 40 years. While in 1960's, surgery was the only option available, late 1980's saw the development of endoscopic sclerotherapy (EST), which totally replaced surgery, [3, 4] in 1990's, a renewed interest has been ushered in the portosystemic shunts as a viable option for paediatric EHPH. [5] [6] [7] [8] In cases of portal hypertension with splenic infarcts, splenectomy with proximal splenorenal shunt has been recommended. We are sharing our experience with distal splenorenal shunt in these cases contrary to the popular belief.
MATERIALS AND METHODS
Total of 44 patients were referred for management of upper gastrointestinal bleed secondary to EHPH from 1998 till 2012 and received a portosystemic shunt. Fourteen out of these cases presented with splenic infarcts and they formed the study group. Splenic infarcts were graded as mild, moderate and severe according to the pre-operative CT portogram. Mild infarct was defined as an infarct <25% of the spleen, moderate infarct was defined as infarcts between 25% Department of Paediatric Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India
African Journal of Paediatric Surgery and 50 % of the spleen while severe infarct was defined as multifocal infarcts or large infarct involving >50% of the area of the spleen. All the patients were operated by the senior author having a fairly long experience of managing portal hypertension of 30 years. Mild infarcts were managed by spleen-preserving distal splenorenal shunt while those with extensive infarcts were subjected to splenectomy and proximal lienorenal (LR) shunt. Cases with moderate infarcts were offered spleen-preserving shunt on the basis of on table decision. Those with spleen-preserving shunts were closely followed in the post-operative period according to a uniform protocol. Clinical examination was regularly done to assess the size of the spleen and note the presence of pain, tenderness in the left intercostal space. An ultrasound Doppler (USGD) was done after 7 days to assess shunt patency while CT portogram (CTP) was repeated at 6 monthly intervals for first year of follow up to see the status of the infarct and thereafter depending on the symptoms and per abdominal spleen size. Height weight chart was made, and the splenic size was recorded. Secondary intervention (EST) was performed for patients who had re-bleed and a shunt block. Shunt was defined as clinically patent when the patient did not have any GI bleed and the varices had regressed on upper gastrointestinal endoscopy (UGIE); and radiologically patent when it could be visualized unequivocally on either USGD or CTP.
RESULTS
Out of the 14 children who formed the study group, 8 were boys and 6 were girls. The age range was 10 months to 12 years with a median of 7 years. The followup period ranged from 2 years to 5 years with a mean of 56 months. There was no mortality, and all the children were seen at least once in 3 months. Out of 14 cases 8 cases had mild infarcts, 3 had moderate infarcts and 3 had severe infarcts [ Table 1 ].
Lienorenal shunt (LRS) was performed in 4 patients; distal splenorenal shunt (DSRS) in 10 patients. Patients with very large spleens or with obvious large/multifocal infarcts (total 4) [ Figure 1] were not considered for a spleen-preserving shunt and those received a lienorenal shunt.
Overall, 12 shunts (85.7%) were found to be patent at follow-up. None of these patients had any GI bleed post-operatively and varices had regressed in all patients, though not completely in some patients. When patency was assessed in context of the type of the shunt procedure; 3/4 (75%) of the LRS, 9/10 (90%) of the DSRS were found patent.
Overall, all 12 patients had direct or indirect evidence of patent shunts. Interestingly, in patients who had received a DSRS, the retroperitoneal collaterals did not show any regression while the oesophageal varices and para-oesophageal collaterals had regressed. In patients with the other types of non-selective shunts, the retroperitoneal collaterals regressed in volume.
In UGIE, varices regressed to some extent in all 12 patients with patent shunts. Similar findings were seen in congestive gastropathy; it resolved completely in 6 patients and improved in 6 patients with patent shunts.
Out of the 10 patients who had undergone a spleenpreserving shunt, 8 had mild infarcts on CT while remaining 2 had moderate infarcts [ Figure 2a ]. Two cases of moderate infarcts reported on pre-operative CT portogram were offered DSRS as on exploration, the degree of infarct did not correlated with the preoperative CT and was found to be less than reported. In 9/10 (90%), we were eventually able to retain the spleen (one patient with moderate infarct developed splenic vein thrombosis on post-operative day 2 and required splenectomy). Spleen completely regressed in the remaining 9 patients. Infarcts also completely We did not encounter any mortality in the present series. Shunt block was seen in 2/14 (14.28%) patients. One of the two has proximal splenorenal shunt done while in another, spleen-preserving shunt was done.
DISCUSSION
Extrahepatic portal venous obstruction is one of the common causes of portal hypertension in childhood; non-cirrhotic portal fibrosis is also among the important causes. Common causes of portal hypertension include extrahepatic portal venous obstruction, non-cirrhotic portal fibrosis, cirrhosis and other causes.
Children with EHPH and upper gastro-intestinal bleed present a difficult clinical challenge. Although the sequelae of portal hypertension namely variceal bleed, splenomegaly and hypersplenism are similar to adults, their impacts on the growing child are different. Physiological differences between adults and children may affect the extrapolation of conclusions derived from longitudinal studies in adults for the bleeding risk in a child with EHPH. Hematemesis, ascitis and obvious splenomegaly have been known to be a common presenting symptom among the cases of portal hypertension in children.
With the advent and refinement of the endoscopic therapies, they are regarded as the mainstay of the management of variceal bleed in children with EHPH. [2] [3] [4] 9, 10] Conventional wisdom states that the children with EHPH stop bleeding as they grow up, but there are no long-term data to support this notion. Proponents of the EST state that the bleeding episodes are not life-threatening in children with EHPH; shunts are difficult and have an associated morbidity of a major surgical procedure. There is also a concern about the chance of hepatic encephalopathy due to a long life span ahead of these children.
On the other hand, large series have demonstrated excellent shunt patency rates and minimal morbidity. [5, 6, 8] Patent shunts have been achieved even with 4 mm-sized veins. [11] In children with EHPH who have received portosystemic shunts either selective or non-selective, the long-term chances of encephalopathy have been found to be negligible. [5, 6, 12] Our shunt patency rates (85.7%) were similar to other large studies. [5, 6] Due to apprehensions of attendants to the asplenic state, our emphasis was towards spleenpreserving shunts unless the spleen was very large or contained severe infarcts, in which we observed that splenomegaly might not regress even in patients with patent shunts. Unfortunately, less has been written in the management of cases of portal hypertension with splenic infarcts because of the popularity of splenectomy and proximal splenorenal shunt in the management of these cases. With the emphasis in the spleen preservation, especially in the paediatric age group, it now becomes essential to analyse these cases and form a guideline for their management. Despite of extensive search, we could not find large case series in the management of cases of portal hypertension with splenic infarct. Partial splenectomy [13] has been done in the management of cases of splenic infarcts due to thrombo-occulsive causes, but there are no reports of any attempt to think for spleen preservation in cases with portal hypertension. We feel that by carefully categorizing them and following them, these cases can be very well managed by spleenpreserving distal splenorenal shunts.
CONCLUSION
In conclusion, we believe that portosystemic shunting in children with EHPH is a viable option. Spleenpreserving distal splenorenal shunt can be considered as a viable option in the management of cases with mild to moderate splenic infarcts.
